Holen Sie sich die Stockscreener-App
17.55
4.20%
-0.77
Schlusskurs vom Vortag:
$18.32
Offen:
$18.15
24-Stunden-Volumen:
1.05M
Relative Volume:
1.17
Marktkapitalisierung:
$465.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-57.91M
KGV:
-12.54
EPS:
-1.3991
Netto-Cashflow:
$-38.14M
1W Leistung:
+13.52%
1M Leistung:
+66.35%
6M Leistung:
+31.95%
1J Leistung:
+203.98%
1-Tages-Spanne:
$17.00
$18.31
1-Wochen-Bereich:
$15.28
$19.40
52-Wochen-Spanne:
$5.7663
$19.40
Tenax Therapeutics Inc Stock (TENX) Company Profile
Firmenname
Tenax Therapeutics Inc
Sektor
Branche
Telefon
919-855-2100
Adresse
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
17.55 | 465.52M | 0 | -57.91M | -38.14M | -1.3991 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-08 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-24 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-14 | Eingeleitet | Guggenheim | Buy |
| 2024-09-30 | Eingeleitet | William Blair | Outperform |
| 2017-05-18 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | Eingeleitet | MLV & Co | Buy |
| 2014-11-18 | Eingeleitet | WallachBeth | Buy |
Alle ansehen
Tenax Therapeutics Inc Aktie (TENX) Neueste Nachrichten
FMR LLC reports 3.94M-share holding in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics: 'Hold' TNX-103 Data August 2026But With Caution Ahead (NASDAQ:TENX) - Seeking Alpha
LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Price to sales forward of Tenax Therapeutics, Inc. – NASDAQ:TENX - TradingView
Tenax lures three new hires with 160,000 stock options - Stock Titan
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 - Investing News Network
(TENX) Risk Channels and Responsive Allocation - Stock Traders Daily
Tenax Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Tenax Therapeutics to Present Phase 3 LEVEL Trial Results for Levosimendan in PH-HFpEF at ESC Congress 2026 - Minichart
Tenax Therapeutics Price Target Maintained With a $27.00/Share by Chardan Capital - Moomoo
Tenax Therapeutics highlights key Phase 3 LEVEL trial - TipRanks
Late-breaking ESC 2026 spot for Tenax (TENX) Phase 3 LEVEL trial data - Stock Titan
Tenax Therapeutics to present Phase 3 trial results at ESC By Investing.com - Investing.com Australia
Tenax Therapeutics to present Phase 3 trial results at ESC - Investing.com
Tenax and Orion Secure Long-Term Levosimendan Supply Deal - The Globe and Mail
TENX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Sharp Stock RallyAnalyst Drop Coverage - dars.gov.et
Tenax Therapeutics Extends Us Regulatory Approval Deadline To December 31, 2035 Via Sixth Amendment To Orion LicenseSEC Filing - TradingView
Tenax Therapeutics, Inc. has extended the deadline for U.S. regulatory approval to December 31, 2035, through the sixth amendment to its licensing agreement with Orion. - Bitget
Tenax Therapeutics (NASDAQ: TENX) deepens Orion deal, extends approval deadline to 2035 - Stock Titan
Tenax Therapeutics Updates Executive and Employee Severance Protections - TipRanks
Tenax Therapeutics (TENX) expands executive and employee severance, CIC plans - Stock Titan
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 2000 Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 2000 Value Benchmark - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM:TENX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 3000E Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell 2000 Dynamic Index - marketscreener.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to Russell Microcap Index - marketscreener.com
Tenax Therapeutics, Inc. Actuals & Estimates (NASDAQ:TENX) - TradingView
Tenax Therapeutics, Inc. Actuals & Estimates (FWB:YBO0) - TradingView
Tenax Therapeutics, Inc. Actuals & Estimates (BOATS:TENX) - TradingView
TENX Forecast — Price Target — Prediction for 2027 - TradingView
TENX Reiterates by Cantor Fitzgerald -- Price Target Maintained at $35.00 - GuruFocus
Here's Why We're Not Too Worried About Tenax Therapeutics' (NASDAQ:TENX) Cash Burn Situation - Moomoo
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), Abbott Laboratories (ABT) and AbbVie (ABBV) - The Globe and Mail
TENX Maintained by Guggenheim -- Price Target Raised to $40 - GuruFocus
TENX Initiated Coverage by Chardan Capital -- Rating Set as Buy - GuruFocus
Guggenheim raises Tenax Therapeutics stock price target on trial confidence By Investing.com - Investing.com Nigeria
Tenax Therapeutics Is Maintained at Buy by Guggenheim - Moomoo
Guggenheim raises Tenax Therapeutics stock price target on trial confidence - Investing.com
(TENX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Tenax Therapeutics (TENX) Edges Higher at $12.0: Testing Key Resistance in Biotech SectorRetail Volume - dars.gov.et
Tenax Therapeutics Inc (TENX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tenax Therapeutics Inc (TENX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tenax Therapeutics Inc (TENX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tenax Therapeutics Inc (TENX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tenax Therapeutics Inc (TENX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tenax Therapeutics Inc (TENX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tenax Therapeutics (TENX) Surges 4.8% as Momentum Builds Above Key SupportEarnings Quality Factor - newsline.com
Tenax Therapeutics Inc (TENX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tenax Therapeutics Inc (TENX) Institutional Confidence - TradingKey
TENX Maintained by Piper Sandler -- Price Target Raised to $50 - GuruFocus
Finanzdaten der Tenax Therapeutics Inc-Aktie (TENX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tenax Therapeutics Inc-Aktie (TENX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
| Rich Stuart | Chief Medical Officer |
Dec 02 '25 |
Buy |
9.01 |
1,000 |
9,006 |
1,266 |
| Giordano Christopher Thomas | CEO |
Nov 18 '25 |
Buy |
7.75 |
1,612 |
12,500 |
1,612 |
| Giordano Christopher Thomas | CEO |
Nov 20 '25 |
Buy |
7.59 |
538 |
4,083 |
2,605 |
| Giordano Christopher Thomas | CEO |
Nov 19 '25 |
Buy |
7.51 |
455 |
3,417 |
2,067 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.25 |
6,000 |
43,490 |
5,000 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.34 |
2,000 |
14,674 |
2,000 |
| Almenoff June Sherie | Director |
Nov 18 '25 |
Buy |
7.52 |
1,900 |
14,280 |
1,993 |
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):